Picture of CanBas Co logo

4575 CanBas Co Share Price

0.000.00%
jp flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-4.58%
3m-54.22%
6m-62.49%
1yr-81.06%
Volume Change (%)
10d/3m-47.91%
Price vs... (%)
52w High-75.6%
50d MA-10.66%
200d MA-48.6%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-24.17%
Return on Equity-42.95%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202430th Jun 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of CanBas Co EPS forecast chart

Profile Summary

CanBas Co Ltd is a Japan-based company mainly engaged in drug development and research. The company is mainly engaged in the basic anticancer drug discovery research (including development of drug discovery concepts, selection of drug candidate compounds using methods based on these concept developments, simple animal studies, and collection and analysis of basic data on anticancer drug candidates that have entered development) and early clinical development (including preclinical studies prior to submission of applications to start clinical trials and the first part of clinical trials).

Directors

Last Annual
June 30th, 2023
Last Interim
December 31st, 2023
Incorporated
January 18th, 2000
Public Since
September 17th, 2009
No. of Shareholders
15,073
No. of Employees
12
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
jp flag iconTokyo Stock Exchange
Shares in Issue
18,023,057
Blurred out image of a map
Address
2-2-1, Ote-machi, NUMAZU-SHI, 410-0801
Web
https://www.canbas.co.jp/
Phone
+81 559543666
Auditors
Deloitte Touche Tohmatsu LLC

4575 Share Price Performance

Upcoming Events for 4575

Q3 2024 CanBas Co Ltd Earnings Release

Dividend For 4575.T - 0.0000 JPY

Similar to 4575

Picture of Astellas Pharma logo

Astellas Pharma

jp flag iconTokyo Stock Exchange

Picture of Astena Holdings Co logo

Astena Holdings Co

jp flag iconTokyo Stock Exchange

Picture of CellSeed logo

CellSeed

jp flag iconTokyo Stock Exchange

Picture of Chugai Pharmaceutical Co logo

Chugai Pharmaceutical Co

jp flag iconTokyo Stock Exchange

FAQ